This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takeuchi, H. Articles by Imaida, K. Search for Related Content PubMed PubMed Citation Articles by Takeuchi, H. Articles by Imaida, K.

Pretreatment with 8-Methoxypsoralen, a Potent Human CYP2A6 Inhibitor, Strongly Inhibits Lung Tumorigenesis Induced by 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Female A/J Mice

¹ Onco-Pathology, Department of Pathology and Host-Defense,
² 1st Department of Surgery, Kagawa Medical University, Kagawa,
³ Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

Human CYP2A6 has been recognized as being involved in the mutagenic activation of promutagens such as the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Methoxsalen (8-methoxypsoralen) was reported to inhibit CYP2A6. In the present study, the inhibitory effects of methoxsalen on NNK-induced lung tumorigenesis in female A/J mice were examined. Female A/J mice were treated with methoxsalen at doses of 50 or 12.5 mg/kg body weight, given by stomach tube, daily for 3 days. One h after the final treatment, NNK was injected i.p. at a dose of 2 mg/mouse. The experiments were terminated 16 weeks after the first methoxsalen treatment, and lung adenomas were analyzed. Pretreatment of methoxsalen significantly reduced tumor incidence from 93.8% to 16.7% (50 mg/kg) and 20.0% (12.5 mg/kg), and tumor multiplicity from 5.97 to 0.23 (50 mg/kg) and 0.25 (12.5 mg/kg) tumors/mouse. These results clearly demonstrated that methoxsalen, a potent human CYP2A6 inhibitor, is a strong chemopreventive agent against NNK-induction of lung tumorigenesis.

This article has been cited by other articles:

				P. Boadas-Vaello, E. Jover, S. Saldana-Ruiz, C. Soler-Martin, C. Chabbert, J. M. Bayona, and J. Llorens Allylnitrile Metabolism by CYP2E1 and Other CYPs Leads to Distinct Lethal and Vestibulotoxic Effects in the Mouse Toxicol. Sci., February 1, 2009; 107(2): 461 - 472. [Abstract] [Full Text] [PDF]

				M. K. Ho and R. F. Tyndale Role of CYP2A6 Genetic Variation on Smoking Behaviors and Clinical Implications ASCO Educational Book, January 1, 2008; 2008(1): 74 - 78. [Abstract] [Full Text] [PDF]

				Y. Weng, C. Fang, R. J. Turesky, M. Behr, L. S. Kaminsky, and X. Ding Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P450 Reductase-Null Mice Cancer Res., August 15, 2007; 67(16): 7825 - 7832. [Abstract] [Full Text] [PDF]

				M. Miyazaki, H. Yamazaki, H. Takeuchi, K. Saoo, M. Yokohira, K.-i. Masumura, T. Nohmi, Y. Funae, K. Imaida, and T. Kamataki Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas Carcinogenesis, November 1, 2005; 26(11): 1947 - 1955. [Abstract] [Full Text] [PDF]

				L. B. von Weymarn, Q.-Y. Zhang, X. Ding, and P. F. Hollenberg Effects of 8-methoxypsoralen on cytochrome P450 2A13 Carcinogenesis, March 1, 2005; 26(3): 621 - 629. [Abstract] [Full Text] [PDF]

				M. R. Spitz, X. Wu, and G. Mills Integrative Epidemiology: From Risk Assessment to Outcome Prediction J. Clin. Oncol., January 10, 2005; 23(2): 267 - 275. [Abstract] [Full Text] [PDF]

				M. Fujieda, H. Yamazaki, T. Saito, K. Kiyotani, M. A. Gyamfi, M. Sakurai, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers Carcinogenesis, December 1, 2004; 25(12): 2451 - 2458. [Abstract] [Full Text] [PDF]